Rising use of heroin and prescription opioids are major contributors to increases in Hepatitis C Virus (HCV) incidence in US young adults since the late 1990s. How best to interrupt transmission and decrease HCV prevalence in young persons who inject drugs (PWID) is uncertain, but modeling studies in older populations support interventions that increase HCV treatment among all PWID. We developed a transmission model of young (aged 15-30 years) PWID, which we fit to state-level US HCV surveillance data, and simulated the potential impact of primary (reducing injection initiation), secondary (increasing cessation, reducing injection partners, or reducing injection drug use relapse), and tertiary (HCV treatment) interventions on incident and prevalent HCV cases. Interventions with primary prevention initiatives (reducing injection initiation) yielded concurrent reductions to HCV incidence and prevalence. Treatment of former PWID led to prevalence reductions but did not reduce incidence. Treatment of current and former PWID without other interventions led to incidence reductions in scenarios with high injection initiation rates, high syringe sharing, and low relapse rates after injection cessation. While these results are specific to Michigan, our approach could be applied in other states conducting HCV surveillance to identify local-level intervention opportunities.
INTRODUCTION
The epidemiology of hepatitis C virus (HCV) in the United States (US) has changed dramatically over the last decade. Increases in HCV incidence among young persons aged approximately 15-30 years have been linked to increases in opioid and injection drug use (IDU), which have been especially large in rural communities (1) (2) (3) (4) (5) . In the US, up to 2.6% of adults have injected drugs in their lifetime and 38-48% of US persons who inject drugs (PWID) have HCV infection, although the prevalence among young PWID is not generally well-characterized (6) (7) (8) (9) (10) . After decades of chronic infection, HCV leads to liver-associated morbidity and mortality (e.g. cirrhosis and hepatocellular carcinoma) (11, 12) .
In the US, transmission modeling studies have shaped HCV screening, treatment, and prevention policies by increasing understanding of HCV transmission dynamics, forecasting prevalence of HCV-related liver diseases, and simulating the impact, costs, and benefits of highly effective directly acting antiviral (DAA) treatments among PWID and other groups disparately burdened by HCV (11, (13) (14) (15) (16) (17) (18) . Several different modeling approaches support the cost-effectiveness of treating PWID with DAAs to interrupt HCV transmission, a strategy known as "treatment as prevention" (14, 15, 17, . One of the few modeling studies focused on young US PWID (<30 years) showed that, in Chicago, a treatment rate of just 5 per 1,000 young PWID could halve HCV prevalence over 10 years in this age group (from 10% to 5%) (14) . While available for Chicago, estimates of HCV prevalence specific to young PWID are not routinely available at the state or local-level throughout the US, limiting the ability to forecast prevalence and 4 evaluate the impact of ongoing interventions. We demonstrate here that routine HCV public health surveillance data collected as part of nationally notifiable and statereportable condition surveillance might be used for this purpose.
HCV incidence and prevalence increases in young adults and adolescents were first identified using HCV public health surveillance data (2, 43, 44) . As part of HCV surveillance, laboratories and physicians report positive HCV lab results to state health departments, who apply standard case definitions to stage HCV as acute or chronic (45, 46 (47) . In addition to under-reporting, there is high variability in capacity to collect risk factor or demographic information, trace contacts, and connect persons with HCV infection to testing and treatment (2, 4) . These limitations have discouraged use of public health surveillance data for HCV transmission modeling.
We developed an HCV transmission model of young PWID in Michigan fit to HCV surveillance data for the state of Michigan (48) that adjusts for case under-reporting and incorporates parameter uncertainty through Latin hypercube sampling of the parameters, a form of stratified random sampling. Model simulations evaluate interventions in a counterfactual framework, including primary prevention (reduced injection initiation), secondary prevention (behavioral initiatives), and tertiary initiatives (HCV treatment), for reducing HCV prevalence and incidence. An evaluation of model fit to data given parameters in the literature is used to identify the consistency of parameter ranges with surveillance data and identify scenarios under which certain interventions may be optimal. This modeling framework could be applied to HCV surveillance data from other states and/or adapted for use in other nationally or statenotifiable conditions.
METHODS
A detailed discussion of the model structure, parameters, initial conditions, surveillance data, and parameter estimation process is available in the Web Methods supplement. Individuals from any of the current PWID classes can stop injecting drugs and move to their adjacent former PWID class at a cessation rate δ while former PWID can begin injecting again after a period of injection abstinence and enter the current PWID class at a relapse rate κ.
Surveillance Data, Parameter Estimation, and Parameter Sampling
The To incorporate parameter uncertainty, Latin hypercube sampling with 5,000 simulations was used to draw a stratified random sample of parameter sets across plausible ranges gathered through literature review (see Web Methods). To optimize model fit to data, we estimated four unknown parameters (the transmission rate [β] and three age-specific injection initiation rates [φ i ]) in each simulation using weighted least squares assuming normally distributed measurement error with variances proportional to the data.
Residual sum of squares values after parameter estimation were used to select the best-fitting 50% of parameter sets to data. To determine if a certain range appeared more consistent with data, we plotted histograms by quartile of fit to the data to visually examine if fit differed along uniformly sampled parameter ranges. Parameter estimation and simulations were run using fminsearch and the ODE15S solver in Matlab.
Potential Interventions
For each of the 50% best-fitting parameter sets (2,500 simulations), the model was resimulated after scaling one or more parameters, which provided counterfactual estimates of expected prevalence and new chronic cases (our measure of incidence) in interferon-based treatments used before 2012, respectively (12) .
RESULTS
We simulated the potential impact of primary (reducing injection initiation), secondary Like all modeling exercises, we made several simplifying assumptions, and we were limited by existing data. Our model only considers HCV acquisition through IDU among young PWID and results are not generalizable to other age or risk groups. Cases with missing risk factor data were assumed to be PWID, consistent with PWID being the most common risk factor for HCV (3, 4, 54 Figure 2) . Treatment interventions assumed a wholly treatment-naïve population, however this is likely realistic given the historically low treatment rates among PWID during the time period under study (55) (56) (57) (58) . Further, treatment was simulated as 100% effective and should therefore be interpreted as the maximum possible treatment effect, given that randomized controlled trials support that approximately 89% of patients are cured of HCV by 12 weeks of DAA therapy (59) .
Conclusions
HCV surveillance data is a valuable data source for understanding HCV transmission and identifying local intervention opportunities among young PWID. In Michigan, primary prevention interventions to decrease injection initiation should be a priority to ensure that HCV prevalence does not further increase among young persons.
Treatment for current PWID reduces prevalence more than treating former PWID, thus persons at all stages of use or recovery should be connected to HCV treatment alongside primary and secondary prevention interventions. 
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Figure 1. Compartmental Model of HCV Transmission among Young PWID in Michigan
States and parameters controlling flows between compartments of an HCV transmission model among young PWID in Michigan. Non-PWID (Z i ) begin injecting drugs (S i ) at a rate f i and acquire acute infection (A i ) through effective contact with an HCV-infected PWID (A j or C j ) of the same or discordant age (Q i,j ) at a transmission rate (b). Chronic infection (C i ) develops at a rate w among a proportion of acute cases, a, and resolves in the remaining 1-a acute cases. Chronic infection can be treated (T i ) at a rate g P , for a duration of s -1 years, after which point susceptibility to reinfection ensues. PWID stop injecting drugs at a rate d and transition to former PWID states (denoted by State Ni ). Former PWID can begin injecting drugs after a period of abstinence at a rate k. Death occurs at a rate µ i , which is elevated among current PWID by a factor h P . Former PWID mortality rates are less disparate from non-PWID by multiplying the current PWID mortality increase factor by a protective factor h N . Subscript i denotes parameter or state age class (1=15-19 years, 2=20-24 years, 3=25-30 years) and subscript j denotes the age group of contacts from whom susceptible current PWID (S i ) can acquire infection. Individuals move through age groups based on the duration predicted by the age range captured in each group (n i , not depicted for simplicity) and new 15 year-olds are added to the non-PWID compartment each year at a rate (n 0 Z 0 , not depicted for simplicity).
Figure 2. Counterfactual Simulation of Single Interventions
The distribution of predicted surveillance-detected HCV prevalence (top) and number of new chronic HCV cases (bottom) for each of 6 interventions among the best-fitting 50% of parameter sets to data are depicted as violin plots. Compared to no intervention (white, right hand side), treating current PWID and decreased injection initiation were associated with the largest predicted reductions to HCV prevalence (A). Reducing injection initiation was associated with the largest predicted reductions to new chronic HCV cases (B). 
